公众号 / 文章乳腺乳腺X线MRUS

减轻COVID-19疫苗接种对乳腺影像检查患者的影响:一种实用方法

Mitigating the Impact of Coronavirus Disease (COVID-19) Vaccinations on Patients Undergoing Breast Imaging Examinations: A Pragmatic Approach.
PubMed 文献 · AJR Am J Roentgenol · 2021-07-22

本文针对COVID-19疫苗接种后乳腺影像发现腋窝淋巴结肿大的增多现象,提出基于临床表现、疫苗接种方式和影像发现的实用管理方法。对于近期接种同侧出现单侧腋窝淋巴结肿大且无其他影像异常者,若接种后6周无可触及淋巴结则报告为良性且无需进一步影像检查;若临床担忧持续至接种后6周则推荐腋窝超声。作者建议新诊断乳腺癌患者应促进影像检查和疫苗接种(大腿或对侧手臂),推荐与ACR BI-RADS Atlas一致。

要点

  • 近期(6周内)同侧疫苗接种后出现单侧腋窝淋巴结肿大且无其他影像异常时,若接种后6周无可触及淋巴结,报告为良性且无需进一步影像检查。
  • 同侧近期接种背景下可触及腋窝淋巴结肿大者,推荐临床腋窝随访。
  • 上述所有场景中,若接种后6周临床担忧持续存在,推荐腋窝超声。

关键影像表现/征象

  • 乳腺影像上识别出疫苗接种后腋窝淋巴结肿大。
  • 在筛查乳腺X线摄影、筛查MRI和乳腺症状诊断性影像检查中,若影像发现仅为近期(过去6周内)接种同侧的单侧腋窝淋巴结肿大,无其他影像异常。

诊断标准与关键数值

  • 在筛查乳腺X线摄影、筛查MRI和乳腺症状诊断性影像检查中,若影像发现仅为近期(过去6周内)接种同侧的单侧腋窝淋巴结肿大且无其他影像异常,接种末剂后6周无可触及淋巴结时,将淋巴结肿大报告为良性且无需进一步影像检查。
  • 同侧近期接种背景下可触及腋窝淋巴结肿大者,推荐临床腋窝随访。
  • 上述所有场景中,若接种后6周临床担忧持续存在,推荐腋窝超声。
  • 近期诊断乳腺癌处于治疗前或治疗期间者,鼓励及时进行推荐的影像检查以及疫苗接种(大腿或对侧手臂)。

临床应用与阅片要点

  • 作者提出:近期(过去6周内)同侧疫苗接种后单侧腋窝淋巴结肿大且无其他影像异常、接种末剂后6周无可触及淋巴结时,报告为良性且无需进一步影像检查。
  • 作者提出:同侧近期接种背景下可触及腋窝淋巴结肿大者,推荐临床腋窝随访。
  • 作者提出:上述所有场景中若接种后6周临床担忧持续存在,推荐腋窝超声。
  • 作者提出:近期诊断乳腺癌处于治疗前或治疗期间者,鼓励及时进行推荐的影像检查以及疫苗接种(大腿或对侧手臂)。
  • 作者提出的推荐与ACR BI-RADS Atlas一致,旨在减少患者焦虑、提供者负担和近期疫苗接种背景下肿大淋巴结不必要的评估费用,并避免大流行期间疫苗接种和乳腺癌筛查的进一步延迟。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Reports of patients with axillary adenopathy identified on breast imaging after coronavirus disease (COVID-19) vaccination are rising. We propose a pragmatic management approach based on clinical presentation, vaccination delivery, and imaging findings. In the settings of screening mammography, screening MRI, and diagnostic imaging workup of breast symptoms, with no imaging findings beyond unilateral axillary adenopathy ipsilateral to recent (within the past 6 weeks) vaccination, we report the adenopathy as benign with no further imaging indicated if no nodes are palpable 6 weeks after the last dose. For patients with palpable axillary adenopathy in the setting of ipsilateral recent vaccination, clinical follow-up of the axilla is recommended. In all these scenarios, axillary ultrasound is recommended if clinical concern persists 6 weeks after vaccination. In patients with a recent breast cancer diagnosis in the pre- or peritreatment setting, prompt recommended imaging is encouraged as well as vaccination (in the thigh or contralateral arm). Our recommendations align with the ACR BI-RADS Atlas and aim to reduce patient anxiety, provider burden, and costs of unnecessary evaluation of enlarged nodes in the setting of recent vaccinations and, also, to avoid further delays in vaccinations and breast cancer screening during the pandemic.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Lehman CD, Lamb LR, D'Alessandro HA, et al. Mitigating the Impact of Coronavirus Disease (COVID-19) Vaccinations on Patients Undergoing Breast Imaging Examinations: A Pragmatic Approach. AJR Am J Roentgenol. 2021. PMID: 33617288. doi:10.2214/AJR.21.25688

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。